Interaction Checker

Interaksi Alpelisib

Alpelisib (Piqray, Vijoice) memiliki 77 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 32 mayor, 45 moderat, 0 minor, dan 0 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (32)

  • Aprepitantpenghambat CYP3A4Mayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Armodafinilstimulan SSPMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Bosentanpenginduksi CYP3A4Mayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Deferasirokssuplemen zat besiMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • DeksametasonkortikosteroidMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • EfavirenzantiretroviralMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Efavirenz, lamivudin, dan tenofovirantiretroviralMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • EslikarbazepinantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • EtravirinantiretroviralMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • FenitoinantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • FenobarbitalbarbituratMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Fentermin dan topiramatstimulan SSPMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • FosfenitoinantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • GriseofulvinantijamurMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • KlobazambenzodiazepinMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Lorlatinibpenginduksi CYP3A4Mayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Mitapivatpenginduksi CYP3A4Mayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Mitotanpenginduksi CYP3A4Mayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Modafinilstimulan SSPMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Nafsilinantibiotik penisilinMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • NevirapinantiretroviralMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • OkskarbazepinantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • PrimidonantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • RifabutinantibiotikMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • RifampisinantibiotikMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • RifapentinantibiotikMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • RitonavirantiretroviralMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • SenobamatantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • Suzetriginpenginduksi CYP3A4Mayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

  • TopiramatantikonvulsanMayor

    CYP3A4 Inducers : Avoid coadministration of VIJOICE with a strong CYP3A4 inducer. (label Alpelisib, Interaksi obat)

Interaksi moderat (45)

  • AzelastinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Azelastin dan flutikasonantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • BeklometasonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • BetametasonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Bromfeniramin, pseudoefedrin, dan dekstrometorfanantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • BudesonidkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • DeflazakortkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • DeksklorfeniraminantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • DesloratadinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • DesonidkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • DifenhidraminantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • DimenhidrinatantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • DoksilaminantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Doksilamin dan piridoksinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • FeksofenadinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • FludrokortisonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • FlunisolidkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • FluosinonidkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • FlutikasonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Flutikason dan salmeterolkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • HalobetasolkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Hidrokodon dan klorfeniraminopioidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • HidrokortisonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • HidroksizinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • KarbinoksaminantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • KlemastinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • KlobetasolkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • KlorfeniraminantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • LevosetirizinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • LoratadinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • MeklizinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • MetilprednisolonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • MometasonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • OlopatadinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Olopatadin dan mometasonantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • PrednisolonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • PrednisonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • PrometazinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Prometazin dan dekstrometorfanantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Prometazin dan kodeinopioidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • SetirizinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • SiklesonidkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • SiproheptadinantihistaminModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • TriamsinolonkortikosteroidModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

Periksa Alpelisib terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.